Evolus: A Wrinkle For Botox

|
About: Evolus, Inc. (EOLS), Includes: AGN, RVNC
by: Et al BioCapital
This article is exclusive for subscribers.
Et al BioCapital
Long/short equity
Summary

Evolus is staking a position as a hybrid biopharma/beauty company.

Jeuveau is Botox with improved cost structure.

We expect Jeuveau to capture second-place in injectable aesthetics market in 2020.

Strong rationale for a positive outlook for Evolus.

Newport Beach, California-based Evolus (NASDAQ:EOLS) is the newest entrant in the injectable aesthetics market. The business is strategized around a single product, a botulinum toxin marketed as Jeuveau. Their strategy focuses solely on